Alan B Goldsobel, MD
Allergy/Immunology · Redwood City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 30
- 6 carriers
- Office
- 1
Offices
1 location · UCSF Health Medical Foundation · 40 clinicians in this group
Hospitals listed: Dominican Hospital. That is not proof they admit you there this week.
Plans that list them
30 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Goldsobel’s office at (650) 701-1882 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
30 of 30 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G39891 · Current
Licensed to practise in California · since 1979 · expires 2028-07-31 · University of Texas Medical Branch at Galveston.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$73,771
Medicare paid this office $73,771 for 287 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Professional service for preparation and provision of 1 or more antigens | 44 | $11,540 | $14 |
| Short return visit (20+ min) | 128 | $11,338 | $78 |
| Return visit (30+ min) | 85 | $10,250 | $110 |
| Test for allergy using allergenic extract | 45 | $7,389 | $3 |
| New patient visit (45+ min) | 51 | $7,319 | $144 |
See all 11 services
| Professional service for preparation and provision of 1 or more antigens | 44 | $11,540 | $14 |
| Short return visit (20+ min) | 128 | $11,338 | $78 |
| Return visit (30+ min) | 85 | $10,250 | $110 |
| Test for allergy using allergenic extract | 45 | $7,389 | $3 |
| New patient visit (45+ min) | 51 | $7,319 | $144 |
| Professional service for multiple injections of allergen | 45 | $6,238 | $11 |
| Test to measure expiratory airflow and volume | 162 | $5,199 | $25 |
| Test to measure the level of nitric oxide gas | 153 | $3,583 | $18 |
| New patient visit (60+ min) | 16 | $3,099 | $194 |
| New patient visit (30+ min) | 17 | $1,616 | $95 |
| Test for allergy using allergenic extract injected into skin | 25 | $1,026 | $8 |
Who their Medicare patients are
287 Original Medicare patients in 2024. Average age 74 · Women 67% · Health risk score 0.89. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 1.
Conditions among them: High blood pressure 64% · Diabetes 22% · Coronary heart disease 19% · Atrial fibrillation 16% · Depression 16% · COPD 15% · Cancer 14% · Chronic kidney disease 11% · Heart failure 8% · Stroke 8%.
The office billed $340,652, Medicare allowed $99,150 and paid $73,771; for 4,592 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 287 | 4,592 | 74 | 0.89 | $340,652 | $73,771 |
| 2023 | 277 | 4,237 | 73 | 0.80 | $316,020 | $67,369 |
| 2022 | 237 | 3,665 | 73 | 0.85 | $244,314 | $54,487 |
| 2021 | 243 | 3,555 | 73 | 0.84 | $208,710 | $62,656 |
| 2020 | 227 | 2,593 | 73 | 0.84 | $124,221 | $44,863 |
| 2019 | 282 | 4,681 | 73 | 0.86 | $174,185 | $69,751 |
| 2018 | 242 | 3,160 | 72 | 0.84 | $134,220 | $50,243 |
| 2017 | 254 | 4,242 | 72 | 0.82 | $154,361 | $60,729 |
| 2016 | 193 | 8,045 | 72 | 0.86 | $329,757 | $173,422 |
| 2015 | 194 | 6,791 | 71 | 0.75 | $290,262 | $143,601 |
| 2014 | 178 | 6,208 | 71 | 0.82 | $215,664 | $100,787 |
| 2013 | 150 | 2,610 | 71 | 0.85 | $107,172 | $48,394 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Professional service for preparation and provision of 1 or more antigens | 46 | $12,267 | $14 |
| Short return visit (20+ min) | 131 | $10,887 | $70 |
| Return visit (30+ min) | 83 | $9,901 | $99 |
| Professional service for multiple injections of allergen | 50 | $5,635 | $10 |
| New patient visit (45+ min) | 42 | $5,544 | $132 |
| Test to measure expiratory airflow and volume | 164 | $4,925 | $22 |
| Test for allergy using allergenic extract | 29 | $4,617 | $3 |
| Test to measure the level of nitric oxide gas | 155 | $3,469 | $16 |
| Long return visit (40+ min) | 18 | $3,179 | $144 |
| New patient visit (60+ min) | 11 | $1,983 | $180 |
| New patient visit (30+ min) | 13 | $1,102 | $85 |
| Test for allergy using allergenic extract injected into skin | 19 | $759 | $7 |
| Short return visit | 13 | $646 | $50 |
2022: 10 services
| Professional service for preparation and provision of 1 or more antigens | 42 | $10,645 | $14 |
| Return visit (30+ min) | 86 | $9,852 | $103 |
| Short return visit (20+ min) | 101 | $6,897 | $63 |
| Professional service for multiple injections of allergen | 52 | $5,360 | $9 |
| New patient visit (45+ min) | 37 | $5,053 | $137 |
| Test for allergy using allergenic extract | 23 | $4,454 | $3 |
| Test to measure expiratory airflow and volume | 123 | $3,436 | $23 |
| Test to measure the level of nitric oxide gas | 108 | $2,217 | $17 |
| Long return visit (40+ min) | 13 | $2,201 | $129 |
| Test for allergy using allergenic extract injected into skin | 13 | $473 | $8 |
2021: 10 services
| Short return visit (20+ min) | 137 | $12,214 | $74 |
| Professional service for preparation and provision of 1 or more antigens | 41 | $11,486 | $15 |
| Return visit (30+ min) | 81 | $10,383 | $112 |
| Professional service for multiple injections of allergen | 46 | $5,456 | $10 |
| Test for allergy using allergenic extract | 19 | $4,968 | $4 |
| New patient visit (45+ min) | 32 | $4,715 | $147 |
| Test to measure expiratory airflow and volume | 91 | $3,352 | $29 |
| Test to measure the level of nitric oxide gas | 78 | $2,000 | $20 |
| New patient visit (60+ min) | 11 | $1,848 | $168 |
| Test for allergy using allergenic extract injected into skin | 11 | $547 | $9 |
2020: 8 services
| Professional service for preparation and provision of 1 or more antigens | 41 | $9,020 | $14 |
| Short return visit (20+ min) | 138 | $8,239 | $50 |
| Return visit (30+ min) | 70 | $7,122 | $88 |
| Professional service for multiple injections of allergen | 51 | $5,709 | $9 |
| New patient visit (45+ min) | 36 | $4,756 | $132 |
| Test for allergy using allergenic extract | 14 | $2,825 | $4 |
| Test to measure expiratory airflow and volume | 67 | $2,114 | $26 |
| Test to measure the level of nitric oxide gas | 47 | $925 | $16 |
2019: 9 services
| Short return visit (20+ min) | 192 | $15,209 | $60 |
| Test for allergy using allergenic extract | 36 | $9,221 | $4 |
| Professional service for preparation and provision of 1 or more antigens | 43 | $9,195 | $13 |
| Test to measure expiratory airflow and volume | 165 | $7,622 | $32 |
| New patient visit (45+ min) | 56 | $7,305 | $130 |
| Return visit (30+ min) | 60 | $6,296 | $90 |
| Professional service for multiple injections of allergen | 47 | $4,861 | $9 |
| Test to measure the level of nitric oxide gas | 102 | $2,423 | $19 |
| Test for allergy using allergenic extract injected into skin | 20 | $962 | $8 |
2018: 8 services
| Short return visit (20+ min) | 161 | $12,602 | $55 |
| Test to measure expiratory airflow and volume | 143 | $6,431 | $30 |
| Professional service for preparation and provision of 1 or more antigens | 38 | $5,881 | $11 |
| Test for allergy using allergenic extract | 20 | $5,666 | $5 |
| New patient visit (45+ min) | 44 | $5,291 | $120 |
| Return visit (30+ min) | 48 | $4,967 | $83 |
| Professional service for multiple injections of allergen | 48 | $3,961 | $8 |
| Test to measure the level of nitric oxide gas | 83 | $1,901 | $18 |
2017: 9 services
| Test for allergy using allergenic extract | 37 | $12,913 | $6 |
| Short return visit (20+ min) | 159 | $12,313 | $58 |
| Professional service for preparation and provision of 1 or more antigens | 37 | $7,806 | $11 |
| Test to measure expiratory airflow and volume | 159 | $6,839 | $30 |
| New patient visit (45+ min) | 53 | $6,163 | $116 |
| Return visit (30+ min) | 57 | $4,697 | $75 |
| Professional service for multiple injections of allergen | 37 | $3,736 | $9 |
| Test to measure the level of nitric oxide gas | 112 | $2,432 | $16 |
| Test for allergy using allergenic extract injected into skin | 24 | $1,029 | $7 |
2016: 9 services
| Short return visit (20+ min) | 135 | $10,395 | $56 |
| Test for allergy using allergenic extract | 24 | $10,177 | $6 |
| Professional service for preparation and provision of 1 or more antigens | 30 | $7,763 | $12 |
| Test to measure expiratory airflow and volume | 123 | $7,094 | $31 |
| New patient visit (45+ min) | 42 | $5,699 | $136 |
| Return visit (30+ min) | 37 | $3,450 | $77 |
| Professional service for multiple injections of allergen | 30 | $3,050 | $8 |
| Test to measure the level of nitric oxide gas | 92 | $2,141 | $17 |
| Test for allergy using allergenic extract injected into skin | 13 | $691 | $7 |
2015: 9 services
| Short return visit (20+ min) | 127 | $9,791 | $57 |
| Professional service for preparation and provision of 1 or more antigens | 34 | $7,747 | $11 |
| Test to measure expiratory airflow and volume | 118 | $6,695 | $33 |
| Return visit (30+ min) | 54 | $5,706 | $82 |
| Test for allergy using allergenic extract | 14 | $5,632 | $6 |
| New patient visit (45+ min) | 30 | $4,163 | $139 |
| Professional service for multiple injections of allergen | 33 | $3,656 | $9 |
| Test to measure the level of nitric oxide gas | 93 | $2,406 | $19 |
| Test for allergy using allergenic extract injected into skin | 11 | $587 | $7 |
2014: 10 services
| Test for allergy using allergenic extract | 31 | $14,837 | $6 |
| Short return visit (20+ min) | 115 | $9,164 | $58 |
| Professional service for preparation and provision of 1 or more antigens | 31 | $8,072 | $12 |
| Test to measure expiratory airflow and volume | 107 | $5,441 | $33 |
| Professional service for multiple injections of allergen | 31 | $4,387 | $9 |
| New patient visit (45+ min) | 30 | $4,317 | $144 |
| Return visit (30+ min) | 34 | $3,272 | $86 |
| Test to measure the level of nitric oxide gas | 71 | $1,673 | $18 |
| New patient visit (30+ min) | 19 | $1,256 | $66 |
| Test for allergy using allergenic extract injected into skin | 18 | $832 | $7 |
2013: 9 services
| Professional service for preparation and provision of 1 or more antigens | 28 | $8,440 | $12 |
| Short return visit (20+ min) | 97 | $6,868 | $58 |
| Test for allergy using allergenic extract | 13 | $5,350 | $6 |
| Test to measure expiratory airflow and volume | 92 | $4,643 | $34 |
| Return visit (30+ min) | 38 | $3,876 | $84 |
| Professional service for multiple injections of allergen | 31 | $3,788 | $10 |
| New patient visit (45+ min) | 13 | $1,733 | $133 |
| Test to measure the level of nitric oxide gas | 59 | $1,435 | $19 |
| New patient visit (30+ min) | 14 | $1,240 | $89 |
Drugs they prescribed that Part D paid
$1,674,857
Pharmacies billed $1,674,857 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,450) in 2024. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 0%.
824 generic and 626 brand-name prescriptions · $1,674,857 in drug cost · 36 antibiotic prescriptions to 29 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | None | 39 | $154,782 | $3,969 |
| Hizentra | Immune globulin | 14 | $146,113 | $10,437 |
| Trelegy Ellipta | None | 111 | $111,300 | $1,003 |
| Dupixent | None | 26 | $98,257 | $3,779 |
| Xolair | None | 22 | $76,196 | $3,463 |
See all 31 drugs
| Dupixent | None | 39 | $154,782 | $3,969 |
| Hizentra | Immune globulin | 14 | $146,113 | $10,437 |
| Trelegy Ellipta | None | 111 | $111,300 | $1,003 |
| Dupixent | None | 26 | $98,257 | $3,779 |
| Xolair | None | 22 | $76,196 | $3,463 |
| Nucala | None | 13 | $49,310 | $3,793 |
| Dulera | None | 46 | $22,591 | $491 |
| Breo Ellipta | None | 41 | $21,332 | $520 |
| Azelastine | None | 150 | $7,522 | $50 |
| Advair Hfa | None | 16 | $7,105 | $444 |
| Arnuity Ellipta | None | 13 | $6,436 | $495 |
| Fluticasone-Salmeterol | None | 24 | $5,284 | $220 |
| Advair Diskus | None | 14 | $5,283 | $377 |
| Ipratropium | None | 93 | $4,369 | $47 |
| Pulmicort Flexhaler | None | 13 | $4,336 | $334 |
| Ryaltris | None | 17 | $4,089 | $241 |
| Albuterol Sulfate Hfa | None | 92 | $3,580 | $39 |
| Montelukast | None | 266 | $2,993 | $11 |
| Wixela Inhub | None | 22 | $2,683 | $122 |
| Breyna | None | 12 | $2,570 | $214 |
| Levalbuterol Tartrate Hfa | None | 24 | $2,557 | $107 |
| Epinephrine | None | 13 | $1,115 | $86 |
| Ventolin Hfa | None | 15 | $829 | $55 |
| Fluticasone Propionate | None | 21 | $570 | $27 |
| Omeprazole | None | 12 | $343 | $29 |
| Lidocaine-Prilocaine | None | 22 | $331 | $15 |
| Clarithromycin | None | 12 | $229 | $19 |
| Hydroxyzine | None | 11 | $219 | $20 |
| Amoxicillin-Clavulanate Potass | None | 18 | $205 | $11 |
| Prednisone | None | 33 | $202 | $6 |
| Mupirocin | None | 14 | $105 | $7 |
Year by year
| 2024 | 1,450 | 254 | 0% (0) | 43% | $1,674,857 |
| 2023 | 1,489 | 259 | 0% (0) | 42% | $1,609,019 |
| 2022 | 1,297 | 246 | 0% (0) | 41% | $1,106,341 |
| 2021 | 1,197 | 222 | 0% (0) | 39% | $931,442 |
| 2020 | 1,338 | 246 | 0% (0) | None | $584,097 |
| 2019 | 1,353 | 258 | 0% (0) | None | $782,877 |
| 2018 | 1,304 | 239 | 0% (0) | 42% | $877,734 |
| 2017 | 1,259 | 223 | 0% (0) | 41% | $1,006,518 |
| 2016 | 1,010 | 152 | 0% (0) | 42% | $1,087,373 |
| 2015 | 1,010 | 167 | 0% (0) | 41% | $744,440 |
| 2014 | 978 | 145 | None | 47% | $361,160 |
| 2013 | 807 | 108 | 0% (0) | 52% | $124,597 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Dupixent | None | 33 | $131,054 | $3,971 |
| Hizentra | Immune globulin | 13 | $99,108 | $7,624 |
| Trelegy Ellipta | None | 93 | $97,166 | $1,045 |
| Dupixent | None | 25 | $89,488 | $3,580 |
| Xolair | None | 22 | $61,263 | $2,785 |
| Nucala | None | 13 | $47,284 | $3,637 |
| Advair Diskus | None | 35 | $27,759 | $793 |
| Dulera | None | 33 | $22,543 | $683 |
| Breo Ellipta | None | 38 | $21,305 | $561 |
| Symbicort | None | 37 | $19,699 | $532 |
| Flovent Hfa | None | 28 | $16,421 | $586 |
| Advair Hfa | None | 20 | $13,060 | $653 |
| Azelastine | None | 166 | $10,782 | $65 |
| Pulmicort Flexhaler | None | 16 | $5,092 | $318 |
| Montelukast | None | 284 | $4,805 | $17 |
| Ryaltris | None | 15 | $4,331 | $289 |
| Albuterol Sulfate Hfa | None | 93 | $4,179 | $45 |
| Wixela Inhub | None | 11 | $3,630 | $330 |
| Ipratropium | None | 71 | $3,278 | $46 |
| Levalbuterol Tartrate Hfa | None | 17 | $1,717 | $101 |
| Ventolin Hfa | None | 17 | $1,435 | $84 |
| Fluticasone Propionate | None | 38 | $1,231 | $32 |
| Mometasone Furoate | None | 15 | $1,000 | $67 |
| Hydroxyzine | None | 12 | $773 | $64 |
| Prednisone | None | 33 | $176 | $5 |
| Paxlovid (Eua) | None | 16 | $153 | $10 |
| Omeprazole | None | 13 | $139 | $11 |
2022: 26 drugs
| Dupixent | 20 | $67,790 | $3,389 |
| Dupixent | 18 | $66,254 | $3,681 |
| Xolair | 24 | $61,929 | $2,580 |
| Nucala | 14 | $46,177 | $3,298 |
| Trelegy Ellipta | 46 | $44,991 | $978 |
| Symbicort | 43 | $30,719 | $714 |
| Breo Ellipta | 40 | $25,149 | $629 |
| Advair Diskus | 37 | $24,509 | $662 |
| Dulera | 43 | $22,288 | $518 |
| Flovent Hfa | 35 | $20,999 | $600 |
| Alvesco | 13 | $18,511 | $1,424 |
| Advair Hfa | 19 | $13,339 | $702 |
| Azelastine | 170 | $11,139 | $66 |
| Wixela Inhub | 17 | $7,038 | $414 |
| Montelukast | 253 | $4,408 | $17 |
| Ipratropium | 65 | $3,544 | $55 |
| Epinephrine | 12 | $3,538 | $295 |
| Azelastine-Fluticasone | 13 | $3,422 | $263 |
| Albuterol Sulfate Hfa | 55 | $3,216 | $58 |
| Mometasone Furoate | 23 | $2,201 | $96 |
| Levalbuterol Tartrate Hfa | 20 | $1,476 | $74 |
| Fluticasone Propionate | 32 | $1,035 | $32 |
| Omeprazole | 12 | $299 | $25 |
| Amoxicillin-Clavulanate Potass | 11 | $142 | $13 |
| Paxlovid (Eua) | 12 | $124 | $10 |
| Prednisone | 29 | $118 | $4 |
2021: 26 drugs
| Dupixent | 33 | $122,230 | $3,704 |
| Nucala | 14 | $47,552 | $3,397 |
| Symbicort | 39 | $30,999 | $795 |
| Xolair | 13 | $29,942 | $2,303 |
| Dulera | 52 | $25,299 | $487 |
| Flovent Hfa | 35 | $20,757 | $593 |
| Advair Diskus | 29 | $20,459 | $705 |
| Breo Ellipta | 31 | $17,832 | $575 |
| Trelegy Ellipta | 14 | $13,904 | $993 |
| Alvesco | 12 | $13,550 | $1,129 |
| Wixela Inhub | 43 | $11,854 | $276 |
| Azelastine | 195 | $10,087 | $52 |
| Advair Hfa | 11 | $7,288 | $663 |
| Montelukast | 231 | $3,845 | $17 |
| Ipratropium | 60 | $3,831 | $64 |
| Mometasone Furoate | 19 | $3,829 | $202 |
| Albuterol Sulfate Hfa | 56 | $3,823 | $68 |
| Arnuity Ellipta | 13 | $3,418 | $263 |
| Zetonna | 13 | $2,991 | $230 |
| Epinephrine | 11 | $2,688 | $244 |
| Azelastine-Fluticasone | 12 | $2,454 | $205 |
| Levalbuterol Tartrate Hfa | 17 | $1,295 | $76 |
| Fluticasone Propionate | 28 | $696 | $25 |
| Hydroxyzine | 15 | $298 | $20 |
| Omeprazole | 15 | $289 | $19 |
| Prednisone | 11 | $68 | $6 |
2020: 28 drugs
| Dupixent | 17 | $66,315 | $3,901 |
| Xolair | 23 | $40,977 | $1,782 |
| Symbicort | 53 | $39,703 | $749 |
| Dulera | 59 | $30,344 | $514 |
| Advair Diskus | 36 | $28,661 | $796 |
| Flovent Hfa | 35 | $24,276 | $694 |
| Breo Ellipta | 21 | $11,899 | $567 |
| Advair Hfa | 23 | $11,728 | $510 |
| Azelastine | 183 | $11,219 | $61 |
| Alvesco | 13 | $10,668 | $821 |
| Spiriva Respimat | 11 | $8,558 | $778 |
| Wixela Inhub | 24 | $7,193 | $300 |
| Atrovent Hfa | 14 | $6,103 | $436 |
| Ipratropium | 78 | $5,930 | $76 |
| Bevespi Aerosphere | 14 | $5,290 | $378 |
| Montelukast | 280 | $5,042 | $18 |
| Arnuity Ellipta | 14 | $4,941 | $353 |
| Albuterol Sulfate Hfa | 70 | $4,835 | $69 |
| Azelastine-Fluticasone | 13 | $4,606 | $354 |
| Mometasone Furoate | 24 | $3,300 | $137 |
| Zetonna | 14 | $3,136 | $224 |
| Ventolin Hfa | 19 | $1,441 | $76 |
| Fluticasone Propionate | 39 | $1,398 | $36 |
| Clarithromycin | 18 | $809 | $45 |
| Omeprazole | 11 | $326 | $30 |
| Olopatadine | 11 | $302 | $27 |
| Amoxicillin-Clavulanate Potass | 13 | $141 | $11 |
| Prednisone | 24 | $104 | $4 |
2019: 27 drugs
| Dupixent | 11 | $34,763 | $3,160 |
| Symbicort | 57 | $33,663 | $591 |
| Alvesco | 22 | $26,631 | $1,210 |
| Dulera | 55 | $23,272 | $423 |
| Flovent Hfa | 32 | $21,651 | $677 |
| Xolair | 12 | $21,386 | $1,782 |
| Advair Diskus | 35 | $20,167 | $576 |
| Breo Ellipta | 31 | $12,040 | $388 |
| Azelastine | 148 | $10,100 | $68 |
| Advair Hfa | 22 | $9,822 | $446 |
| Wixela Inhub | 16 | $6,810 | $426 |
| Bevespi Aerosphere | 18 | $6,513 | $362 |
| Montelukast | 286 | $5,471 | $19 |
| Proair Hfa | 40 | $4,839 | $121 |
| Arnuity Ellipta | 16 | $4,376 | $273 |
| Ipratropium | 73 | $4,030 | $55 |
| Asmanex Hfa | 16 | $3,472 | $217 |
| Mometasone Furoate | 12 | $3,411 | $284 |
| Ventolin Hfa | 34 | $2,452 | $72 |
| Clarithromycin | 38 | $1,757 | $46 |
| Olopatadine | 23 | $1,659 | $72 |
| Albuterol Sulfate Hfa | 21 | $1,449 | $69 |
| Fluticasone Propionate | 49 | $1,374 | $28 |
| Omeprazole | 11 | $402 | $37 |
| Prednisone | 44 | $213 | $5 |
| Hydroxyzine | 13 | $97 | $7 |
| Mupirocin | 11 | $96 | $9 |
2018: 23 drugs
| Advair Diskus | 39 | $32,693 | $838 |
| Alvesco | 37 | $26,135 | $706 |
| Symbicort | 45 | $25,353 | $563 |
| Flovent Hfa | 51 | $23,941 | $469 |
| Breo Ellipta | 32 | $17,430 | $545 |
| Dulera | 35 | $15,221 | $435 |
| Azelastine | 159 | $11,868 | $75 |
| Advair Hfa | 26 | $11,105 | $427 |
| Spiriva Respimat | 22 | $10,061 | $457 |
| Zetonna | 20 | $5,264 | $263 |
| Mometasone Furoate | 19 | $5,086 | $268 |
| Flovent Diskus | 11 | $5,057 | $460 |
| Montelukast | 278 | $4,895 | $18 |
| Incruse Ellipta | 12 | $4,779 | $398 |
| Proair Hfa | 43 | $4,130 | $96 |
| Ipratropium | 68 | $3,568 | $52 |
| Dymista | 14 | $2,722 | $194 |
| Olopatadine | 13 | $2,565 | $197 |
| Ventolin Hfa | 30 | $1,917 | $64 |
| Fluticasone Propionate | 41 | $1,229 | $30 |
| Clarithromycin | 25 | $1,206 | $48 |
| Hydroxyzine | 31 | $713 | $23 |
| Prednisone | 29 | $291 | $10 |
2017: 23 drugs
| Alvesco | 49 | $22,541 | $460 |
| Dulera | 37 | $20,670 | $559 |
| Advair Diskus | 38 | $20,645 | $543 |
| Symbicort | 41 | $17,009 | $415 |
| Flovent Hfa | 31 | $14,550 | $469 |
| Azelastine | 142 | $9,910 | $70 |
| Advair Hfa | 22 | $8,755 | $398 |
| Breo Ellipta | 12 | $7,002 | $584 |
| Incruse Ellipta | 12 | $6,972 | $581 |
| Atrovent Hfa | 11 | $6,094 | $554 |
| Flovent Diskus | 15 | $4,831 | $322 |
| Ipratropium | 70 | $4,403 | $63 |
| Asmanex Hfa | 18 | $4,316 | $240 |
| Montelukast | 236 | $4,253 | $18 |
| Proair Hfa | 43 | $3,928 | $91 |
| Zetonna | 11 | $3,491 | $317 |
| Mometasone Furoate | 12 | $2,820 | $235 |
| Ventolin Hfa | 36 | $2,024 | $56 |
| Fluticasone Propionate | 62 | $1,768 | $29 |
| Clarithromycin | 33 | $1,346 | $41 |
| Hydroxyzine | 39 | $843 | $22 |
| Prednisone | 42 | $299 | $7 |
| Amoxicillin-Clavulanate Potass | 13 | $209 | $16 |
2016: 23 drugs
| Nucala | 11 | $30,186 | $2,744 |
| Dulera | 48 | $16,847 | $351 |
| Alvesco | 41 | $16,092 | $392 |
| Flovent Hfa | 29 | $13,206 | $455 |
| Advair Diskus | 24 | $11,982 | $499 |
| Symbicort | 22 | $10,351 | $470 |
| Azelastine | 105 | $8,175 | $78 |
| Spiriva | 15 | $7,984 | $532 |
| Spiriva Respimat | 20 | $6,714 | $336 |
| Montelukast | 216 | $4,810 | $22 |
| Advair Hfa | 14 | $4,763 | $340 |
| Nasonex | 17 | $4,500 | $265 |
| Incruse Ellipta | 11 | $4,073 | $370 |
| Atrovent Hfa | 13 | $3,846 | $296 |
| Proair Hfa | 35 | $3,055 | $87 |
| Ipratropium | 51 | $2,806 | $55 |
| Fluticasone Propionate | 79 | $1,988 | $25 |
| Hydroxyzine | 19 | $975 | $51 |
| Ventolin Hfa | 14 | $830 | $59 |
| Clarithromycin | 16 | $598 | $37 |
| Prednisone | 17 | $134 | $8 |
| Azithromycin | 11 | $112 | $10 |
| Pantoprazole | 11 | $48 | $4 |
2015: 21 drugs
| Advair Diskus | 53 | $28,604 | $540 |
| Spiriva | 34 | $14,649 | $431 |
| Alvesco | 27 | $12,853 | $476 |
| Symbicort | 24 | $8,861 | $369 |
| Azelastine | 79 | $7,029 | $89 |
| Dulera | 24 | $6,750 | $281 |
| Advair Hfa | 18 | $6,513 | $362 |
| Flovent Hfa | 16 | $6,102 | $381 |
| Montelukast | 212 | $4,852 | $23 |
| Nasonex | 18 | $4,662 | $259 |
| Spiriva Respimat | 12 | $3,704 | $309 |
| Proair Hfa | 35 | $3,688 | $105 |
| Atrovent Hfa | 14 | $3,680 | $263 |
| Dymista | 17 | $3,416 | $201 |
| Asmanex | 11 | $2,691 | $245 |
| Ipratropium | 73 | $2,570 | $35 |
| Clarithromycin | 24 | $1,749 | $73 |
| Fluticasone Propionate | 83 | $1,603 | $19 |
| Hydroxyzine | 14 | $804 | $57 |
| Amoxicillin-Clavulanate Potass | 17 | $354 | $21 |
| Omeprazole | 11 | $200 | $18 |
2014: 19 drugs
| Gamunex-C | Immune globulin | 24 | $37,802 | $1,575 |
| Advair Diskus | None | 82 | $33,516 | $409 |
| Spiriva | None | 43 | $16,252 | $378 |
| Nasonex | None | 38 | $11,613 | $306 |
| Symbicort | None | 26 | $10,000 | $385 |
| Alvesco | None | 21 | $8,403 | $400 |
| Advair Hfa | None | 18 | $6,984 | $388 |
| Montelukast | None | 176 | $6,764 | $38 |
| Azelastine | None | 62 | $6,252 | $101 |
| Dulera | None | 17 | $5,553 | $327 |
| Patanol | None | 12 | $3,632 | $303 |
| Flovent Hfa | None | 12 | $3,631 | $303 |
| Proair Hfa | None | 38 | $3,367 | $89 |
| Fluticasone Propionate | None | 100 | $3,083 | $31 |
| Ipratropium | None | 68 | $2,441 | $36 |
| Clarithromycin | None | 25 | $1,487 | $59 |
| Ventolin Hfa | None | 12 | $923 | $77 |
| Levocetirizine Dihydrochloride | None | 13 | $557 | $43 |
| Pantoprazole | None | 22 | $176 | $8 |
2013: 18 drugs
| Advair Diskus | 80 | $26,856 | $336 |
| Spiriva | 48 | $18,035 | $376 |
| Nasonex | 54 | $13,324 | $247 |
| Dulera | 24 | $7,638 | $318 |
| Montelukast | 117 | $5,952 | $51 |
| Flovent Hfa | 19 | $5,632 | $296 |
| Alvesco | 21 | $4,558 | $217 |
| Azelastine | 51 | $3,781 | $74 |
| Proair Hfa | 35 | $3,094 | $88 |
| Nexium | 14 | $3,043 | $217 |
| Patanol | 12 | $2,856 | $238 |
| Fluticasone Propionate | 55 | $2,403 | $44 |
| Ipratropium | 43 | $1,292 | $30 |
| Clarithromycin | 14 | $1,156 | $83 |
| Levocetirizine Dihydrochloride | 27 | $860 | $32 |
| Hydroxyzine | 16 | $586 | $37 |
| Azithromycin | 13 | $137 | $11 |
| Pantoprazole | 14 | $106 | $8 |
Money from drug and device companies
$3,936 in 2025
| 2025 | 13 | 39 | None | $3,936 |
| 2024 | 10 | 21 | $1,513 | $2,119 |
| 2023 | 11 | 58 | $1,300 | $2,931 |
| 2022 | 12 | 54 | $11,200 | $12,014 |
| 2021 | 15 | 52 | $17,700 | $18,447 |
| 2020 | 14 | 51 | $5,550 | $6,621 |
| 2019 | 19 | 86 | $16,761 | $20,371 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Fasenra | $3,027 | 12 payments
|
| GlaxoSmithKline | Nucala | $272 | 6 payments
|
| ARS Pharmaceuticals Operations | Neffy | $173 | 5 payments
|
| Ionis Pharmaceuticals | Dawnzera | $143 | 2 payments
|
| CSL Behring | Hizentra | $117 | 5 payments
|
| Amgen | Tezspire | $33 | 1 payment
|
See all 39 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-03 | Fasenra | $4 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-03 | Fasenra | $17 |
| GlaxoSmithKline | Meals · 2025-11-19 | None | $125 |
| Ionis Pharmaceuticals | Meals · 2025-11-11 | Dawnzera | $124 |
| CSL Behring | Meals · 2025-11-10 | Andembry | $20 |
| Pharming Healthcare | Meals · 2025-11-05 | Ruconest | $20 |
| Genzyme | Meals · 2025-11-05 | Dupixent | $13 |
| ARS Pharmaceuticals Operations | Meals · 2025-10-30 | Neffy | $3 |
| Grifols USA | Meals · 2025-10-22 | Xembify | $15 |
| GlaxoSmithKline | Meals · 2025-10-21 | Trelegy Ellipta | $13 |
| CSL Behring | Meals · 2025-10-15 | Hizentra | $39 |
| Ionis Pharmaceuticals | Meals · 2025-10-07 | Dawnzera | $20 |
| Genzyme | Meals · 2025-10-02 | Dupixent | $16 |
| Galderma Laboratories L.P. | Meals · 2025-10-02 | Nemluvio | $31 |
| ARS Pharmaceuticals Operations | Meals · 2025-09-10 | Neffy | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-03 | Tezspire | $24 |
| GlaxoSmithKline | Meals · 2025-08-27 | Nucala | $25 |
| BioCryst US Sales Co. | Meals · 2025-08-06 | Orladeyo | $30 |
| CSL Behring | Meals · 2025-07-22 | Andembry | $21 |
| ARS Pharmaceuticals Operations | Meals · 2025-07-21 | Neffy | $9 |
| Octapharma USA | Meals · 2025-07-16 | Cutaquig | $27 |
| GlaxoSmithKline | Meals · 2025-06-23 | Nucala | $2 |
| GlaxoSmithKline | Meals · 2025-05-29 | Trelegy Ellipta | $14 |
| CSL Behring | Meals · 2025-05-14 | Hizentra | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-07 | Fasenra | $125 |
| ARS Pharmaceuticals Operations | Meals · 2025-04-30 | Neffy | $19 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-04-25 | None | $700 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-04-25 | None | $2,000 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-21 | Fasenra | $20 |
| CSL Behring | Meals · 2025-04-15 | Haegarda | $16 |
| ARS Pharmaceuticals Operations | Meals · 2025-04-01 | Neffy | $125 |
| Teva Pharmaceuticals USA | Meals · 2025-03-31 | Albuterol Sulfate | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-19 | Airsupra | $30 |
| GlaxoSmithKline | Meals · 2025-03-02 | None | $93 |
| Amgen | Meals · 2025-02-27 | Tezspire | $33 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-01-29 | None | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-29 | None | $24 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-01-29 | None | $48 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-21 | Fasenra | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,119
| Takeda Pharmaceuticals U.S.A. | None | $1,513 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $144 | 7 payments
|
| Genentech USA | Xolair | $122 | 1 payment
|
| Pharming Healthcare | Ruconest | $80 | 3 payments
|
| CSL Behring | Haegarda | $79 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $55 | 2 payments
|
| Blueprint Medicines | Ayvakit | $42 | 1 payment
|
| Octapharma USA | Cutaquig | $37 | 1 payment
|
| Amgen | Actimmune | $34 | 1 payment
|
| GlaxoSmithKline | Nucala | $14 | 1 payment
|
2023: $2,931
| GlaxoSmithKline | Nucala | $1,610 | 15 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $402 | 15 payments
|
| CSL Behring | Hizentra | $393 | 12 payments
|
| Genzyme | Dupixent | $185 | 3 payments
|
| Merck Sharp & Dohme | None | $157 | 1 payment
|
| Grifols USA | Xembify | $46 | 2 payments
|
| Octapharma USA | Cutaquig | $45 | 2 payments
|
| Genentech USA | Xolair | $32 | 1 payment
|
| ALK-Abello | Odactra | $24 | 1 payment
|
| Hospira | Octagam Immune Globulin (Human) | $23 | 1 payment
|
| Hikma Pharmaceuticals USA | Ryaltris | $14 | 1 payment
|
2022: $12,014
| GlaxoSmithKline | Trelegy Ellipta | $9,414 | 21 payments
|
| OptiNose US | Xhance | $2,114 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $217 | 10 payments
|
| Genzyme | Dupixent | $117 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $32 | 2 payments
|
| Novartis Pharmaceuticals | Xolair | $24 | 1 payment
|
| ALK-Abello | Odactra | $20 | 1 payment
|
| Teva Pharmaceuticals USA | Airduo Digihaler | $19 | 1 payment
|
| CSL Behring | Hizentra | $15 | 1 payment
|
| Genentech USA | Xolair | $15 | 1 payment
|
| Hikma Pharmaceuticals USA | Kloxxado | $14 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Takhzyro | $13 | 1 payment
|
2021: $18,447
| GlaxoSmithKline | Trelegy Ellipta | $13,463 | 23 payments
|
| Optinose US | Xhance | $2,750 | 2 payments
|
| Merck Sharp & Dohme | None | $1,000 | 1 payment
|
| Octapharma USA | Cutaquig | $750 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $138 | 9 payments
|
| kaleo | Auvi-Q | $92 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $88 | 5 payments
|
| Pfizer | Eucrisa | $36 | 2 payments
|
| Grifols USA | Xembify | $26 | 1 payment
|
| Horizon Therapeutics plc | Actimmune | $25 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $25 | 1 payment
|
| Genentech USA | Xolair | $18 | 1 payment
|
| CSL Behring | Hizentra | $13 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Cuvitru | $13 | 1 payment
|
| Uswm | Symjepi | $12 | 1 payment
|
2020: $6,621
| GlaxoSmithKline | Trelegy Ellipta | $5,024 | 20 payments
|
| Merck Sharp & Dohme | None | $750 | 1 payment
|
| Octapharma USA | Cutaquig | $228 | 1 payment
|
| Sanofi-Aventis U.S. | Dupixent | $177 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $153 | 12 payments
|
| Genzyme | Dupixent | $59 | 3 payments
|
| OptiNose US | Xhance | $46 | 2 payments
|
| Novartis Pharmaceuticals | Xolair | $43 | 2 payments
|
| Pfizer | Eucrisa | $33 | 2 payments
|
| Grifols USA | Xembify | $28 | 1 payment
|
| Circassia Pharmaceuticals | Niox Vero | $25 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Cuvitru | $20 | 1 payment
|
| Covis Pharma GmbH | Alvesco | $20 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $14 | 1 payment
|
2019: $20,371
| OptiNose US | Xhance | $12,211 | 25 payments
|
| Merck Sharp & Dohme | Mk-7264 | $4,689 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $1,318 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $1,002 | 11 payments
|
| Genzyme | Dupixent | $162 | 3 payments
|
| GlaxoSmithKline | Nucala | $161 | 12 payments
|
| Teva Pharmaceuticals USA | Cinqair | $154 | 3 payments
|
| ALK-Abello | Odactra | $147 | 3 payments
|
| Octapharma USA | Cutaquig | $122 | 1 payment
|
| Novartis Pharmaceuticals | Xolair | $116 | 8 payments
|
| Regeneron Pharmaceuticals | Dupixent | $64 | 3 payments
|
| Pfizer | Eucrisa | $46 | 3 payments
|
| Genentech USA | Xolair | $39 | 2 payments
|
| Kaleo | Auvi-Q | $28 | 2 payments
|
| Horizon Therapeutics plc | Actimmune | $25 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $22 | 1 payment
|
| Philips Electronics North America | Reusable Vest | $22 | 1 payment
|
| Covis Pharma B.V. | Alvesco | $21 | 1 payment
|
| Pharming Healthcare | Ruconest | $19 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Hikma Pharmaceuticals USA · Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study · 2019 | Their institution | $211,260 |
| GlaxoSmithKline, LLC. · A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para · 2024 | Their institution | $194,331 |
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2023 | Their institution | $167,915 |
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2022 | Their institution | $156,134 |
| CIPLA USA INC. · U-Fs-Mu-As3120 · 2019 | Their institution | $144,089 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Sar443765 in Adult Participants With Moderate To Severe Asthma · 2025 | Their institution | $143,495 |
| AstraZeneca Pharmaceuticals LP · A Randomized, Placebo-Controlled, Double-Blind, Multicenter, 12 Week, 3-Way, Partial-Replicate Crossover Pharmacodynamic Study To Assess the Equivalence of Budesonide and Albuterol (Bda) Delivered By Mdi Hfo Compared With Bda Delivered By Mdi Hfa in Participants With Asthma · 2025 | Their institution | $141,546 |
| AstraZeneca Pharmaceuticals LP · Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study To Assess Efficacy and Safety of Multiple Dose Levels of Inhaled Azd8630 · 2025 | Their institution | $134,368 |
| Novartis Pharmaceuticals Corporation · A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study To Assess the Efficacy and Safety of Csj117, When Added To Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. · 2021 | Their institution | $131,921 |
| AstraZeneca Pharmaceuticals LP · A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 To 52 Week Variable Length Study To Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler Mdi Relative To Budesonide and Formoterol Fumarate Mdi and Symbicort Pmdi in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2022 | Their institution | $116,976 |
| Novartis Pharmaceuticals Corporation · A Three-Year, Multi-Center, Double-Blind, Extension Study To Evaluate the Long-Term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab'S Phase III Studies in Food Allergy · 2024 | Their institution | $114,582 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma · 2025 | Their institution | $96,299 |
| Teva Pharmaceuticals USA, Inc. · A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Tev-48574 in Adults With T2-Low/Non-T2 Severe Uncontrolled Asthma · 2021 | Their institution | $85,647 |
| GlaxoSmithKline, LLC. · A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para · 2025 | Their institution | $80,876 |
| Teva Pharmaceuticals USA, Inc. · A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Assess the Safety, Efficacy and Pharmacodynamics of Tev 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma · 2021 | Their institution | $77,950 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma · 2023 | Their institution | $66,609 |
| CIPLA USA INC. · A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, 4-Week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 Micro Gm Inhalation Powder With Advair Diskus 100/50 Micro Gm in Asthma Patients · 2020 | Their institution | $60,657 |
| AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2020 | Their institution | $52,025 |
| AIMMUNE THERAPEUTICS, INC. · Phase 2 Study of Ar201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy · 2020 | Their institution | $49,599 |
| Novartis Pharmaceuticals Corporation · A Three-Year, Multi-Center, Double-Blind, Extension Study To Evaluate the Long-Term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab'S Phase III Studies in Food Allergy · 2023 | Their institution | $45,238 |
| GlaxoSmithKline, LLC. · A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm · 2021 | Their institution | $44,038 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma · 2024 | Their institution | $43,571 |
| SANOFI US SERVICES INC. · A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma · 2021 | Their institution | $39,148 |
| Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis · 2020 | Their institution | $35,647 |
| Merck Sharp & Dohme Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Monthstudy To Evaluate the Efficacy and Safety of Mk-7264 in Adult Participants With Chroniccough Pn030 · 2019 | Their institution | $35,033 |
| AstraZeneca Pharmaceuticals LP · A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 To 52 Week Variable Length Study To Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler Mdi Relative To Budesonide and Formoterol Fumarate Mdi and Symbicort Pmdi in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2023 | Their institution | $33,878 |
| AstraZeneca Pharmaceuticals LP · A Randomized, Placebo-Controlled, Double-Blind, Multicenter, 12 Week, 3-Way, Partial-Replicate Crossover Pharmacodynamic Study To Assess the Equivalence of Budesonide and Albuterol (Bda) Delivered By Mdi Hfo Compared With Bda Delivered By Mdi Hfa in Participants With Asthma · 2024 | Their institution | $32,450 |
| Teva Pharmaceuticals USA, Inc. · A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Assess the Safety, Efficacy and Pharmacodynamics of Tev 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma · 2022 | Their institution | $32,352 |
| Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day Bid in Subjects With Chronic Sinusitis With Or Without the Presence of Nasal Polyps. Opn-Flu-Cs-3205. · 2019 | Their institution | $30,818 |
| GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2022 | Their institution | $30,596 |
| AIMMUNE THERAPEUTICS, INC. · Phase 2 Study of Ar201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy · 2021 | Their institution | $29,383 |
| Teva Pharmaceuticals USA, Inc. · A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Tev-48574 in Adults With T2-Low/Non-T2 Severe Uncontrolled Asthma · 2022 | Their institution | $28,452 |
| CIPLA USA INC. · U-Fs-Mu-As3120 · 2020 | Their institution | $28,167 |
| GlaxoSmithKline, LLC. · A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro · 2019 | Their institution | $26,821 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Sar443765 in Adult Participants With Moderate To Severe Asthma · 2024 | Their institution | $24,018 |
| Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day (Bid) in Subjects With Chronic Sinusitis With Or Without the Presence of Nasal Polyps. Opn-Flu-Cs-3205. · 2020 | Their institution | $22,095 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma · 2025 | Their institution | $21,792 |
| Hikma Pharmaceuticals USA · Fluticasone / Salmeterol Powder, 100mcg/50mcg Multicenter Clinical Endpoint Study · 2020 | Their institution | $20,340 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Proof-of-Concept (Poc) Study To Assess the Efficacy, Safety, and Tolerability of Sar440340 and the Coadministration of Sar440340 · 2019 | Their institution | $20,195 |
| SANOFI US SERVICES INC. · A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma · 2023 | Their institution | $19,120 |
| Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihistamines · 2021 | Their institution | $18,264 |
| AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2021 | Their institution | $17,966 |
| Novartis Pharmaceuticals Corporation · A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study To Assess the Efficacy and Safety of Csj117, When Added To Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. · 2020 | Their institution | $17,465 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma · 2025 | Their institution | $17,388 |
| CIPLA USA INC. · 2023 | Their institution | $16,539 |
| GlaxoSmithKline, LLC. · A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm · 2022 | Their institution | $16,523 |
| Teva Pharmaceuticals USA, Inc. · A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma · 2024 | Their institution | $15,088 |
| Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day (Bid) in Subjects With Chronic Sinusitis With Or Without the Presence of Nasal Polyps. Opn-Flu-Cs-3205. · 2022 | Their institution | $15,077 |
| Teva Pharmaceuticals USA, Inc. · A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Tev-48574 in Adults With T2-Low/Non-T2 Severe Uncontrolled Asthma · 2020 | Their institution | $14,803 |
| GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2021 | Their institution | $12,785 |
| Novartis Pharmaceuticals Corporation · A Multi-Center, Double-Blinded and Open-Label Extension Study To Evaluate the Efficacy and Safety of Ligelizumab As Retreatment, Self-Administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies Cqge031c2302, Cqge031c2303, Cqge031c2202 Or Cqge031c1301 · 2021 | Their institution | $12,475 |
| AstraZeneca Pharmaceuticals LP · A Phase II, Randomized, Double-Blind, Single-Dose, Placebo-Controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study To Compare the Bronchodilatory Effect and Safety of Pt007 As Mdi To Placebo Mdi and Open-Label Ventolin Evohaler in Adult Participants With Asthma Mitchell · 2025 | Their institution | $11,783 |
| CHIESI USA, INC. · Ccd-05993aa3-01 · 2019 | Their institution | $10,989 |
| SANOFI US SERVICES INC. · A Randomized, Multicenter, 3-Arm, Double-Blind, Placebo-Controlled Study To Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of Sar439794 in Peanut Alle · 2019 | Their institution | $10,637 |
| SANOFI US SERVICES INC. · A Long-Term Extension Study To Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study · 2023 | Their institution | $10,500 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma · 2022 | Their institution | $10,500 |
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2024 | Their institution | $10,486 |
| Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis · 2019 | Their institution | $8,877 |
| SANOFI US SERVICES INC. · Open-Label Extension Study To Evaluate the Long-Term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in A Previous Dupilumab Asthma Clinical Study · 2019 | Their institution | $8,858 |
| GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul · 2021 | Their institution | $8,400 |
| Novartis Pharmaceuticals Corporation · A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study To Assess the Efficacy and Safety of Csj117, When Added To Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. · 2022 | Their institution | $8,176 |
| SANOFI US SERVICES INC. · A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma · 2022 | Their institution | $7,304 |
| Merck Sharp & Dohme Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study To Evaluate the Efficacy and Safety of Mk-7264 in Adult Participants With Chronic Cough Pn030 · 2021 | Their institution | $6,783 |
| AstraZeneca Pharmaceuticals LP · A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of Pt001 To Placebo and Open-Label Spiriva Respimat in Subjects With Persistent Asthma · 2020 | Their institution | $6,756 |
| SANOFI US SERVICES INC. · Open-Label, Interventional, Cohort Study To Evaluate Long-Term Safety of Dupilumab in Patients With Moderate To Severe Asthma Who Completed the Traverse-Lts12551 Clinical Trial · 2020 | Their institution | $6,324 |
| Novartis Pharmaceuticals Corporation · A Multi-Center, Double-Blinded and Open-Label Extension Study To Evaluate the Efficacy and Safety of Ligelizumab As Retreatment, Self-Administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies Cqge031c2302, Cqge03 · 2022 | Their institution | $6,198 |
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2021 | Their institution | $5,870 |
| AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2022 | Their institution | $5,643 |
| GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2025 | Their institution | $4,898 |
| GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2024 | Their institution | $3,913 |
| AstraZeneca Pharmaceuticals LP · A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 To 52 Week Variable Length Study To Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler Mdi Relative To Budesonide and Formoterol Fumarate Mdi and Symbicort Pmdi in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2025 | Their institution | $3,874 |
| SANOFI US SERVICES INC. · A Randomized Double Blind Placebo Controlled Parallel Goup 12 Week Proof of Concept Study To Assess the Efficacy, Safety, and Tolerability of Sar440340 and the Coadministration of Sar440340 and Dupilu · 2020 | Their institution | $3,500 |
| AIMMUNE THERAPEUTICS, INC. · 2023 | Their institution | $3,386 |
| SANOFI US SERVICES INC. · A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma · 2024 | Their institution | $3,225 |
| AstraZeneca Pharmaceuticals LP · A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of Pt001 To Placebo and Open-Label Spiriva Respimat in Subjects With Persistent Asthma · 2019 | Their institution | $3,009 |
| Novartis Pharmaceuticals Corporation · A Three-Year, Multi-Center, Double-Blind, Extension Study To Evaluate the Long-Term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab'S Phase III Studies in Food Allergy · 2025 | Their institution | $2,669 |
| SANOFI US SERVICES INC. · A Randomized Multicenter 3-Arm Double Blind Placebo Controlled Study To Assess the Safety Tolerability and Pharmacodynamics of Repeated Sublingual Daily Adminstration of Sar439794 in Peanut Allergic A · 2020 | Their institution | $2,122 |
| Novartis Pharmaceuticals Corporation · A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study To Assess the Efficacy and Safety of Csj117, When Added To Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. · 2023 | Their institution | $2,000 |
| SANOFI US SERVICES INC. · A Randomized, Multicenter, 3-Arm, Double-Blind, Placebo-Controlled Study To Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of Sar439794 in Peanut Alle · 2020 | Their institution | $1,797 |
| Merck Sharp & Dohme Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study To Evaluate the Efficacy and Safety of Mk-7264 in Adult Participants With Chronic Cough Pn030 · 2020 | Their institution | $1,480 |
| AstraZeneca Pharmaceuticals LP · Multicentre, Double-Blind, Randomized, Parallel Group, Phase 3 Safety Extension Study To Evaluate the Safety and Tolerability of Benralizumab (Medi-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-Acting Beta2 Agonist Bora · 2019 | Their institution | $1,387 |
| SANOFI US SERVICES INC. · A Randomized Multicenter 3-Arm Double Blind Placebo Controlled Study To Assess the Safety Tolerability and Pharmacodynamics of Repeated Sublingual Daily Adminstration of Sar439794 in Peanut Allergic A · 2019 | Their institution | $1,337 |
| Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis · 2022 | Their institution | $1,232 |
| Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day (Bid) in Subjects With Chronic Sinusitis With Or Without the Presence of Nasal Polyps. Opn-Flu-Cs-3205. · 2021 | Their institution | $1,227 |
| CIPLA USA INC. · 2024 | Their institution | $1,000 |
| Novartis Pharmaceuticals Corporation · A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess Efficacy and Safety of Remibrutinib (Lou064) in Adult and Adolescent Participants With Ige-Mediated Food Allergy. · 2025 | Their institution | $910 |
| SANOFI US SERVICES INC. · Open-Label, Interventional, Cohort Study To Evaluate Long-Term Safety of Dupilumab in Patients With Moderate To Severe Asthma Who Completed the Traverse-Lts12551 Clinical Trial · 2019 | Their institution | $600 |
| AstraZeneca Pharmaceuticals LP · A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 To 52 Week Variable Length Study To Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler Mdi Relative To Budesonide and Formoterol Fumarate Mdi and Symbicort Pmdi in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2024 | Their institution | $371 |
| GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2023 | Their institution | $232 |
| Merck Sharp & Dohme Corporation · A 12-Week Study To Assess the Efficacy and Safety Ofaf-219 Mk-7264 in Subjects With Treatment Refractorychronic Cough · 2021 | Their institution | $61 |
| Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihistamines · 2023 | Their institution | $60 |
Professional record
- NPI
- 1063528321
- Licence
- CA G39891California G39891: Current · expires 2028-07-31
- Trained
- University of Texas Medical Branch at Galveston, 1977
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207K00000X (207K00000X)
- Mailing address
- 4050 Moorpark Ave, San Jose, CA, 95117
- NPI first listed
- 2006-08-21
- NPI last updated
- 2016-02-25
This is when the NPI record was last certified, not a medical board exam.